FDA Approves RHA Redensity Eye for Infraorbital Volume Deficiencies
FDA approves RHA Redensity Eye for correction of moderate to severe tissue volume deficiencies in the infraorbital region in adults ages 22 and older.
Useful takeaways from this story.
FDA approves RHA Redensity Eye for correction of moderate to severe tissue volume deficiencies in the infraorbital region in adults ages 22 and older.
Building the complete brief
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
The useful part
FDA approves RHA Redensity Eye for correction of moderate to severe tissue volume deficiencies in the infraorbital region in adults ages 22 and older.
Keep reading in the app
Open the app view to save this story, compare related coverage, and continue from the same source.